Search Within

GME, Medicine

Formats
  1. Meeting Abstract (682)
  2. Journal Article (538)
  3. Review (141)
  4. Editorial (63)
  5. Research Letter (57)
  6. Correspondence (24)
  7. Miscellaneous (6)
  8. Book Section (5)
  9. Conference Paper (4)
  10. Guidelines (3)
Groups
  1. Graduate Medical Education (1523)
  2. Department of Medicine (1196)
  3. Hematology-Oncology Fellows (996)
  4. Hematologic Malignancies, Division of (703)
  5. Solid Tumor Oncology Division (613)
  6. Weinberg Fellows (570)

More Groups

People
  1. Kylee Maclachlan (143)
  2. Gunjan Shah (135)
  3. Michael Scordo (131)
  4. Sergio Giralt (123)
  5. Saad Usmani (120)
  6. Alexander Lesokhin (111)

More People

Years
  1. 2025 (112)
  2. 2024 (365)
  3. 2023 (404)
  4. 2022 (323)
  5. 2021 (154)
  6. 2020 (73)

More Years

Publications
  1. Blood (249)
  2. Journal of Clinical Oncology (218)
  3. Clinical Lymphoma, Myeloma and Leukemia (46)
  4. Clinical Cancer Research (43)
  5. Annals of Oncology (37)
  6. Cancer Research (34)

More Publications

Publishers
  1. American Society of Hematology (285)
  2. American Society of Clinical Oncology (250)
  3. Elsevier Inc. (199)
  4. Nature Publishing Group (105)
  5. American Association for Cancer Research (101)
  6. Oxford University Press (69)

More Publishers

Results (1523)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Functional geriatric assessment tests predict toxicity rates in functional high risk myeloma patients treated with daratumumab, carfilzomib, lenalidomide and dexamethasone in a prospective clinical trial
    Meeting Abstract

    Shmuel, R.; Tellem, R.; Gatt, M. E.; Lavi, N.; Ganzel, C.; Luttwak, E.; Chubar, E.; Rouvio, O.; Vaxman, I.; Pasvolsky, O.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors
    Meeting Abstract

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A niche driven mechanism determines response to ATRA and a mutation-independent therapeutic approach for MDS and AML
    Meeting Abstract

    Mosialou, I.; Ali, A. M.; Cuesta-Dominguez, A.; Labella, R.; Vgenopoulou, V.; Bisikirska, B.; Galan-Diez, M.; Wang, A. Q.; Bewersdorf, J. P.; Liang, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs BTKi therapies in 1L CLL: An international real-world study
    Meeting Abstract

    Lamanna, N.; Brown, J. R.; Ujjani, C. S.; Eyre, T. A.; Manzoor, B.; Ghosh, N.; Roeker, L.; Davids, M. S.; Coombs, C. C.; Skarbnik, A. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities
    Meeting Abstract

    Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save